SCHEMBL3370885

SCHEMBL3370885

COc1cc(C(=N)N)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
PRSS1 P07477 6/20 0.51
HTT P42858 2/20 0.50
TSHR P16473 1/20 0.50
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
ACHE P22303 1/20 0.48
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
KMT2A Q03164 1/20 0.47
PRSS2 P07478 2/20 0.47
PRSS3 P35030 2/20 0.47
CA9 Q16790 1/20 0.46
C1S P09871 1/20 0.46
TUBB4A P04350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22291210 0.83 CA12 (0.55) MAPTPRSS1KMT2APRSS2PRSS3
SCHEMBL22291213 0.80 PRSS1 (0.43) CYP3A4PRSS1HTTTSHRAPOBEC3A
3,4,5-Trimethoxybenzamide SCHEMBL1326890 0.78 TSHR (0.76) CYP3A4MAPTHTTTSHRAPOBEC3A
SCHEMBL3368852 0.78 PRSS1 (0.77) CYP3A4PRSS1TSHRALDH1A1PRSS2
SCHEMBL2766557 0.78 HTT (0.57) CYP3A4MAPTHTTTSHRAPOBEC3A
3,4,5-Trimethoxybenzamide SCHEMBL4381076 0.77 TSHR (0.73) CYP3A4MAPTHTTTSHRAPOBEC3A
Hydrochloric Acid SCHEMBL6287246 0.77 PRSS1 (0.77) CYP3A4PRSS1TSHRALDH1A1PRSS2
Hydrochloric Acid SCHEMBL6794567 0.76 PRSS1 (0.53) PRSS1PRSS2PRSS3C1S
Hydrochloric Acid SCHEMBL6645355 0.76 PRSS1 (0.53) PRSS1PRSS2PRSS3C1S
SCHEMBL22291110 0.75 F10 (0.55) PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020160148-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-06 WO disclosed
CN-105899504-A Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection 豪夫迈·罗氏有限公司 2016-08-24 CN disclosed
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-1324015-C Pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
CN-1630644-A Novel pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2005-06-22 CN disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 CYP3A4 76/4885MAPT 4559/4885PRSS1 283/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK CYP3A4 70/4885MAPT 4458/4885PRSS1 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.